ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Radiotherapy as an antihemorrhagic approach in gastric cancer: the RANTIGA study.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastric bleeding is a major symptom of locally advanced gastric cancer and a significant cause of mortality. Management options include surgery, endoscopic interventions, embolization and radiotherapy (RT). Although palliative RT appears effective for hemorrhage control, evidences are limited to underpowered retrospective studies from Asia, with issues of patient heterogeneity and response evaluation criteria. This study is a multicenter retrospective analysis carried out across Italian radiation oncology centers to evaluate real-world outcomes of hemostatic RT in patients with bleeding gastric cancer. METHODOLOGY: Clinical and dosimetric data were retrospectively collected for patients with active bleeding gastric cancer treated across twelve Italian radiation oncology centers. The primary endpoint was to evaluate hemoglobin stabilization or improvement at four weeks post-treatment. Secondary outcomes included treatment parameters, acute toxicity profile and time to rebleeding.
resultsBetween January 2018 and October 2024, 100 patients receiving hemostatic RT were collected for the analysis. The median age was 77 years, 68% of cases had advanced disease and 41% of patients were pretreated with chemotherapy. The most frequently administered dose was 39 Gy BED10 (range: 9.6-53.1) with a schedule of 30 Gy in 10 fractions. The primary endpoint was achieved in 95/100 patients (95%) indicating stabilization or improvement in Hb levels without the need for post-treatment transfusions. Only 12 patients experienced acute toxicity, of whom 2 (3.3%) presenting grade 3 nausea. Rebleeding symptoms occurred in 38.5% of cases (median interval of 164 days).
conclusionThis national, retrospective, multicenter study suggests that palliative gastric RT is a feasible, effective and well-tolerated approach in this cohort of patients with bleeding gastric cancer, providing hemostatic control and stabilizing hemoglobin levels. Prospective trials are warranted to better define the role of RT, particularly in terms of dose and fractionation based on the disease setting and patient characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.